Nkarta Inc
NKTX
Market Cap$124.18M
Close$
$-0.77
144.1% downside
Current Fair Value
144.1% downsideOvervalued by 144.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.18 Million |
|---|---|
| Enterprise Value | $151.98 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.6 |
| Beta | 0.73 |
| Outstanding Shares | 73,916,477 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.16 |
|---|---|
| PEG | -13.92 |
| Price to Sales | - |
| Price to Book Ratio | 0.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.13 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.53 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nkarta Inc
95 employeesNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell en...